Komori

Q&A from the Full-Year Results Briefing for the Fiscal Year Ended September 2026

Q&A summaryFull year, FY ending Sep 2026Published 2026-11-17 17:30

The company published the questions received and its answers from the full-year results briefing for the fiscal year ended September 2026. The main topics were clinical trial progress, U.S. development, manufacturing capabilities, financing, and the earnings forecast for the fiscal year ending September 2027.

In short

  • For the domestic additional Phase III trial in acute spinal cord injury, the company will strengthen coordination with clinical trial sites, patient organisations and others to accelerate patient enrolment.
  • For the fiscal year ending September 2027, research and development expenses are expected to increase temporarily due to U.S. development and preparations for the manufacturing of HGF drug substance, among other factors. The company forecasts revenue of ¥127 million and an operating loss of ¥1,773 million.
  • The financing of approximately ¥2.2 billion is expected to fund preparations for the U.S. Phase III trial, establishment of manufacturing capabilities for HGF drug substance, domestic manufacturing and working capital.

What they reported

this period against the same period a year earlier, and where they now expect the year to end

Sales

¥442.0m+513.9%vs a year earlier
FY FY25/9¥72.0mFY FY26/9¥442.0m
FY24/9FY25/9FY26/9 · this year0100200300¥mQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4±0%+6%+1494%+526%this yearvs same quarter last yearlast year
Sales by quarter
Period¥m
FY24/9 Q118.0
FY24/9 Q225.0
FY24/9 Q318.0
FY24/9 Q419.0
FY25/9 Q118.0
FY25/9 Q217.0
FY25/9 Q318.0
FY25/9 Q419.0
FY26/9 Q118.0
FY26/9 Q218.0
FY26/9 Q3287.0
FY26/9 Q4119.0
last forecast 332.0
result 442.0
Full year: forecast against result, ¥m+33.1% vs the last forecast
Next year's forecast: ¥127.0m
Old and new forecast from the company's results releases
Forecast

Revenue for the fiscal year ending September 2027 is forecast at ¥127 million.

2027 年 9 月期の業績予想は、売上高 127 百万円、営業損失 1,773 百万円、当期純損失 1,775 百万円です。
The forecast for the fiscal year ending September 2027 is revenue of ¥127 million, an operating loss of ¥1,773 million and a net loss of ¥1,775 million.

Operating profit

−¥0.8bnloss narrowedvs a year earlier
FY FY25/9−¥0.9bnFY FY26/9−¥0.8bn
FY24/9FY25/9FY26/9 · this year-0-0-0¥bnQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4▲▼▲▼this yearvs same quarter last yearlast year
Operating profit by quarter
Period¥bn
FY24/9 Q1-0.2
FY24/9 Q2-0.2
FY24/9 Q3-0.2
FY24/9 Q4-0.2
FY25/9 Q1-0.2
FY25/9 Q2-0.3
FY25/9 Q3-0.2
FY25/9 Q4-0.2
FY26/9 Q1-0.2
FY26/9 Q2-0.3
FY26/9 Q3-0.1
FY26/9 Q4-0.2
last forecast -1.0
result -0.8
Full year: forecast against result, ¥bnloss narrowed vs the last forecast
Next year's forecast: −¥1.8bn
Old and new forecast from the company's results releases
Why

Research and development expenses are expected to increase temporarily because U.S. development, HGF drug substance manufacturing, the establishment of new manufacturing capabilities and manufacturing-related work toward filing for approval of a treatment for vocal fold scarring will proceed simultaneously.

米国における脊髄損傷急性期の開発準備、HGF 原薬の製造、新たな製造体制の構築、声帯瘢痕治療薬の承認申請に向けた製造関連業務など、複数の開発案件が同時に進行するため、研究開発費が一時的に大きく増加する見込みです。
Research and development expenses are expected to increase significantly on a temporary basis because multiple development projects will proceed simultaneously, including preparations for the development of acute spinal cord injury treatment in the United States, HGF drug substance manufacturing, the establishment of new manufacturing capabilities and manufacturing-related work toward filing for approval of a treatment for vocal fold scarring.
Forecast

An operating loss of ¥1,773 million is forecast for the fiscal year ending September 2027.

2027 年 9 月期の業績予想は、売上高 127 百万円、営業損失 1,773 百万円、当期純損失 1,775 百万円です。
The forecast for the fiscal year ending September 2027 is revenue of ¥127 million, an operating loss of ¥1,773 million and a net loss of ¥1,775 million.

Net profit

−¥0.8bnloss narrowedvs a year earlier
FY FY25/9−¥0.9bnFY FY26/9−¥0.8bn
FY24/9FY25/9FY26/9 · this year-0-0-0¥bnQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4▲▼▲▼this yearvs same quarter last yearlast year
Net profit by quarter
Period¥bn
FY24/9 Q1-0.2
FY24/9 Q2-0.2
FY24/9 Q3-0.2
FY24/9 Q4-0.2
FY25/9 Q1-0.2
FY25/9 Q2-0.3
FY25/9 Q3-0.2
FY25/9 Q4-0.2
FY26/9 Q1-0.2
FY26/9 Q2-0.3
FY26/9 Q3-0.1
FY26/9 Q4-0.2
last forecast -1.0
result -0.8
Full year: forecast against result, ¥bnloss narrowed vs the last forecast
Next year's forecast: −¥1.8bn
Old and new forecast from the company's results releases
Forecast

A net loss of ¥1,775 million is forecast for the fiscal year ending September 2027.

2027 年 9 月期の業績予想は、売上高 127 百万円、営業損失 1,773 百万円、当期純損失 1,775 百万円です。
The forecast for the fiscal year ending September 2027 is revenue of ¥127 million, an operating loss of ¥1,773 million and a net loss of ¥1,775 million.

Everything else in the deck

New initiatives

what they said they're starting
  • The company will prepare for the U.S. Phase III trial in acute spinal cord injury until it is Ready-to-Go and able to start promptly.
  • The company will establish manufacturing capabilities for recombinant human HGF drug substance using a new manufacturing method.
  • The company will advance the domestic manufacturing of HGF drug substance.
  • The company will advance commercial-scale manufacturing and other preparations toward filing for approval of a treatment for vocal fold scarring.
  • The company will raise approximately ¥2.2 billion and allocate the proceeds to development, its manufacturing platform and working capital.

What decks usually leave out

COMPUTED = worked out by Komori from reported numbers; the rest are stated in this deck

Margins and overheads

where each ¥100 of sales goes
Computed
a year ago-1262.5%now-183.9%

Financial targets

the last five years against the target (green band), where one is stated
Computed
Return on equity-65.7%
profit earned on shareholders' money
−12.1 pts on last year
-68%-39%-11%FY22/9FY23/9FY24/9FY25/9FY26/9FY22/9: -12.5%FY23/9: -35.5%FY24/9: -36.6%FY25/9: -53.6%FY26/9: -65.7%-65.7%
Return on equity
Period%
FY22/9-12.5
FY23/9-35.5
FY24/9-36.6
FY25/9-53.6
FY26/9-65.7
Equity ratio57.1%
how much of the balance sheet is owned outright
−4.4 pts on last year
55%72%89%FY22/9FY23/9FY24/9FY25/9FY26/9FY22/9: 86.8%FY23/9: 76.6%FY24/9: 75.8%FY25/9: 61.5%FY26/9: 57.1%57.1%
Equity ratio
Period%
FY22/986.8
FY23/976.6
FY24/975.8
FY25/961.5
FY26/957.1

Yearly figures are computed by Komori from J-Quants results data (ROE = net profit ÷ average equity). The last point is this year's forecast or latest figure. Targets show only when this deck states them.

Investor Q&A

what investors pushed on, and whether they got an answer
3 of 13answers dodged the question
where the questions went
Progress of the domestic additional Phase III trial in acute spinal cord injury
1
Relationship between Stemirac injection and HGF protein products
1
Development status of the treatment for vocal fold scarring
1
Orphan designation for the treatment for vocal fold scarring
1
Partnering negotiations for acute spinal cord injury development in the United States
1
Non-dilutive funding for U.S. development
1
Increase in expenses for the fiscal year ending September 2027
1
Financing of approximately ¥2.2 billion
1
Partnering policy for the U.S. Phase III trial
1
Use of proceeds from the financing
1
Exercise prices of the stock acquisition rights
1
Reasons for participating in the third-party allotment
1
Holding period of strategic shareholders
1
Progress of the domestic additional Phase III trial in acute spinal cord injury

Has patient enrolment been delayed?

The number of patients is limited, transportation and eligibility confirmation are required, and the patient population is further constrained by the stricter selection criteria. The company will strengthen coordination with clinical trial sites, patient organisations and surrounding medical institutions to accelerate enrolment.

Hedged
Relationship between Stemirac injection and HGF protein products

If Stemirac injection receives full approval, will the need for HGF protein products decline?

The two products differ in such respects as the timing of treatment and mechanisms of action, and are not simply competitors. Accordingly, the company believes that the need for HGF protein products will not decline.

Straight
Development status of the treatment for vocal fold scarring

When will the top-line data from the Phase III trial be announced?

The final patient's follow-up is scheduled to be completed in December 2026, and the top-line data are scheduled to be announced in the first half of 2027.

Straight
Orphan designation for the treatment for vocal fold scarring

What is the status of the application for orphan designation?

The company is continuing discussions with the Ministry of Health, Labour and Welfare and preparing for an early application.

Hedged
Partnering negotiations for acute spinal cord injury development in the United States

How far have negotiations with potential partners progressed?

The company plans to continue preparations until it is Ready-to-Go and able to promptly initiate the Phase III trial, but it has not disclosed specific details of negotiations with individual companies due to confidentiality obligations and other considerations.

Dodged
Non-dilutive funding for U.S. development

How much public funding and other support is expected?

This is an important option, but because the selection and amount have not been determined, it is not yet at the stage where a specific amount can be incorporated into the financing plan.

Dodged
Increase in expenses for the fiscal year ending September 2027

What is the reason for the substantial increase in the operating loss?

Multiple development projects will proceed simultaneously, causing research and development expenses to increase temporarily. This is not simply an increase in fixed costs, but the result of concentrated development investment required for future approval, launch and overseas expansion.

Straight
Financing of approximately ¥2.2 billion

Why is financing necessary now?

The company needs to execute its medium- to long-term strategy of transitioning from a drug-discovery venture to a biopharmaceutical company while domestic and overseas development and the establishment of an HGF manufacturing platform proceed simultaneously.

Straight
Partnering policy for the U.S. Phase III trial

Will the company proceed on the assumption that it will secure a partner, or is in-house development also being considered?

The company will prioritise securing a partnering company, but will also consider in-house development if a partnership cannot be established. However, conducting the trial using financing raised independently is not realistic at present.

Hedged
Use of proceeds from the financing

Specifically, what will the ¥2.2 billion be used for?

The proceeds are expected to fund preparations for the U.S. Phase III trial, preparations for establishing manufacturing capabilities for HGF drug substance using a new manufacturing method, domestic manufacturing of HGF drug substance and working capital.

Straight
Exercise prices of the stock acquisition rights

What was the basis for setting the exercise prices at ¥600 and ¥1,000?

The exercise prices were set after comprehensively considering funding needs, the share price level, development milestones, the feasibility of the financing and the impact of dilution, with the aim of linking the increase in corporate value resulting from development progress to the financing.

Straight
Reasons for participating in the third-party allotment

Why did 丸石製薬 and ゼノアックホールディングス participate?

Both companies have long been important business partners, and this investment represents continued support from existing strategic shareholders.

Straight
Holding period of strategic shareholders

Will they continue to hold the shares for the long term after the capital increase?

The investment is based on long-term business relationships, but the company cannot guarantee how long the shares will be held in the future.

Dodged

How straight each answer was: a number or commitment = straight; a direction without a number = hedged; no answer = dodged.

Not mentioned in this deck

16
Company KPIsBy businessWhat movedCapital spendingShare buybackDividendSelf-rating against planForecast assumptionsRisks priced into the forecastMid-term plan targetsA stated financial targetOrders and backlogPrice and volumeStore or site countHeadcountMarket size and share